DBP's first income from sales of Temodex in Latin Amerika
Today DBP has received their first payment from CLOSTER PHARMA for 3 units of Temodex that will be delivered from the supplier to Colombia shortly.
As previously announced, Double Bond Pharmaceutical and CLOSTER PHARMA SAS (Colombia) signed a distribution agreement for Temodex in Mexico, Brazil, Colombia, Peru, Ecuador and Costa Rica in September 2018. At the beginning of November same year, Double Bond Pharmaceutical and Closter Pharma organized an exchange of experience where eight doctors from leading hospitals in Colombia were able to meet and exchange experience with developers, manufacturers and users of Temodex in Minsk, Belarus. For three days, they had the opportunity to see with their own eyes how Temodex is manufactured and used on site by Belarussian experts. As the following step of the collaboration, Double Bond Pharmaceutical has received its first purchase order for 10 units of Temodex (/mbpublicbinaryproxy/Main/12720/2685669/954389.pdf).
"We are very pleased that cooperation with our Latin American partners continues to progress as planned and starts generating our first income. There is a great interest in Temodex in different parts of the world and we are happy to provide doctors to patients with brain cancer with our innovative product" - commented Igor Lokot, CEO of Double Bond Pharmaceutical. “Latin America is a large market and can generate a lucrative business for Drugsson AB".
More about Temodex: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. Video presentation: https://youtu.be/iweOQPq316o
More about Drugsson AB: www.drugsson.com
More about Closter Pharma: https://www.emis.com/php/company-profile/CO/Closter_Pharma_SAS_en_Reorganizacion_en_2652694.html
More about collaboration with Closter Pharma: /mbpublicbinaryproxy/Main/12720/2650414/930429.pdf, /mbpublicbinaryproxy/Main/12720/2630320/917487.pdf
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 25 of February 2019.
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.